Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.

ABSTRACT:

Background

Colorectal cancer (CRC) is the third most common cancer worldwide, with highly variable prognosis and response to treatment. A large subset of patients does not respond to standard treatments or develops resistance. As an alternative, adoptive immunotherapy based on chimeric antigen receptor (CAR)-transduced immune cells has been proposed, however with significant adverse events. We therefore evaluated alternative CAR targets already tested in other tumour types and employed the natural killer cell line NK-92 for CAR transduction because of its more favourable toxicity profile.

Methods

As an alternative antigen, we considered mesothelin (MSLN), the most represented target in CAR-based clinical studies for solid tumours. MSLN RNA expression was analysed in large se

SUBMITTER: Torchiaro E 

PROVIDER: S-EPMC11616334 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature